Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Non-Current Deferred Tax Liability (2022 - 2025)

ProQR Therapeutics' Non-Current Deferred Tax Liability history spans 4 years, with the latest figure at $3.0 million for Q4 2025.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 4.8% to $3.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.0 million, a 4.8% decrease, with the full-year FY2025 number at $3.0 million, down 4.8% from a year prior.
  • Non-Current Deferred Tax Liability hit $3.0 million in Q4 2025 for ProQR Therapeutics, down from $3.2 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for PRQR hit a ceiling of $4.0 million in Q4 2023 and a floor of $3.0 million in Q4 2025.
  • Historically, Non-Current Deferred Tax Liability has averaged $3.5 million across 4 years, with a median of $3.5 million in 2022.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: increased 5.74% in 2023 and later dropped 21.81% in 2024.
  • Tracing PRQR's Non-Current Deferred Tax Liability over 4 years: stood at $3.8 million in 2022, then grew by 5.74% to $4.0 million in 2023, then dropped by 21.81% to $3.2 million in 2024, then decreased by 4.8% to $3.0 million in 2025.
  • Business Quant data shows Non-Current Deferred Tax Liability for PRQR at $3.0 million in Q4 2025, $3.2 million in Q4 2024, and $4.0 million in Q4 2023.